Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Enlicitide Formulations
NCT06880874Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Primary completion
- May 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enlicitide in hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to 24 hours, Area Under the Concentration-Time Curve from Time 0 to Last at 168 hours and 2 more. Started Apr 2025; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06880874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880874.